文献速递淋巴瘤

艾德拉尼联合来那度胺和利妥昔单抗治疗复发难治性淋巴瘤的安全性和耐受性:肿瘤学临床试验联盟A051201和A051202 1期试验

Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.
PubMed 文献 · Lancet Haematol · 2017-03-15

两项1期试验评估艾德拉尼联合来那度胺和利妥昔单抗治疗复发套细胞淋巴瘤(A051201)和滤泡性淋巴瘤(A051202)的最大耐受剂量。2013年7月9日至2014年9月30日纳入11例患者,前8例中4例出现意外剂量限制性毒性,移除利妥昔单抗后3例中2例出现3级皮疹、1例出现3级AST升高,两项试验均永久关闭,未达到安全性和耐受性主要终点。

要点

  • 前8例患者中4例出现意外剂量限制性毒性,症状出现于治疗开始后9-20天,与利妥昔单抗输注时间重合。
  • 移除利妥昔单抗后,3例新增患者中2例出现3级皮疹、1例出现3级AST升高,两项试验均永久关闭。
  • 套细胞淋巴瘤患者最常见3-4级不良事件为ALT升高(3例中2例,67%)和皮疹(3例中2例,67%)。

核心结论

  • 艾德拉尼、来那度胺和利妥昔单抗联合方案在这些试验中毒性过大,未达到安全性和耐受性主要终点。
  • 这些试验作为警示:研究生物制剂联合方案时应仔细评估脱靶效应、药物相互作用和新出现的毒性,且绝不能在临床试验之外进行。

研究设计与样本

  • A051201(套细胞淋巴瘤)和A051202(滤泡性淋巴瘤)均为1期试验,主要终点为艾德拉尼联合来那度胺和利妥昔单抗的安全性和耐受性,所有分析均按意向治疗进行。
  • A051201纳入组织学确诊的复发套细胞淋巴瘤且既往未接受过来那度胺或艾德拉尼的患者,起始口服来那度胺15 mg(第1-21天,28天周期)、口服艾德拉尼150 mg每日两次(连续28天周期)、静脉利妥昔单抗375 mg/m²(第1周期每周一次)。
  • A051202纳入组织学确诊的复发滤泡性淋巴瘤且距末次含利妥昔单抗方案进展时间≥6个月的患者,起始口服来那度胺10 mg(第1-21天,每28天)、口服艾德拉尼150 mg每日两次(连续28天周期)、静脉利妥昔单抗375 mg/m²(第1周期第8、15、22天及第2周期第1天)。
  • 2013年7月9日至2014年9月30日共纳入11例患者(套细胞淋巴瘤3例,滤泡性淋巴瘤8例)。

主要发现

  • 前8例患者中4例出现意外剂量限制性毒性:4级脓毒症综合征、4级低血压伴3级皮疹和发热、4级天冬氨酸氨基转移酶(AST)或丙氨酸氨基转移酶(ALT)升高伴发热、3级肺部感染伴3级斑丘疹。
  • 症状出现于治疗开始后9-20天,与利妥昔单抗输注时间重合。
  • 两项研究修改方案移除利妥昔单抗后,3例新增患者中2例出现3级皮疹、1例出现3级AST升高。
  • 套细胞淋巴瘤患者最常见3-4级不良事件为ALT升高(3例中2例,67%)和皮疹(3例中2例,67%);滤泡性淋巴瘤患者为中性粒细胞减少(8例中5例,63%)和皮疹(8例中4例,50%)。
  • 安全性和耐受性主要终点未达到。

临床怎么用

  • 作者认为该联合方案毒性过大,这些试验作为警示:研究生物制剂联合方案时应仔细评估脱靶效应、药物相互作用和新出现的毒性,且绝不能在临床试验之外进行。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A new generation of biological and targeted agents might potentially replace traditional cytotoxic agents in lymphoma. Lenalidomide plus rituximab was felt to be a safe and promising backbone based on available data. Idelalisib is an oral phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor that has promising activity as a monotherapy in refractory indolent lymphomas. The primary objective of these two trials was to determine the maximum tolerated dose of lenalidomide in combination with rituximab and idelalisib in relapsed follicular and mantle cell lymphoma. METHODS: A051201 (mantle cell lymphoma) and A051202 (follicular lymphoma) were phase 1 trials. Patients with histologically documented relapsed mantle cell lymphoma who had not received previous lenalidomide or idelalisib (A051201) were started with oral lenalidomide 15 mg on days 1-21 in a 28 day cycle, oral idelalisib 150 mg twice a day with continuous 28-day cycles, and intravenous rituximab 375 mg/m2 weekly during cycle 1. Patients with histologically documented relapsed follicular lymphoma and time to progression 6 months or longer from last rituximab-containing regimen (A051202) were started with oral lenalidomide 10 mg on days 1-21 every 28 days and oral idelalisib 150 mg twice a day with continuous 28-day cycles, and intravenous rituximab 375 mg/m2 on cycle 1, day 8, day 15, day 22, and cycle 2, day 1. The primary endpoints of the studies were safety and tolerability of combining idelalisib with lenalidomide and rituximab in patients with relapsed mantle cell lymphoma (A051201) and relapsed follicular lymphoma (A051202). All analyses were by intention to treat. The trials were registered at ClinicalTrials.gov, number NCT01838434 (A051201) and number NCT01644799 (A051202). FINDINGS: Between July 9, 2013, and Sept 30, 2014, 11 patients (three with mantle cell lymphoma and eight with follicular lymphoma) were enrolled. Among the first eight patients, four experienced unexpected dose-limiting toxicities: grade 4 sepsis syndrome, grade 4 hypotension with grade 3 rash and fevers, grade 4 aspartate aminotransferase (AST) or alanine aminotransferase (ALT) elevation with fevers, and grade 3 pulmonary infection with grade 3 maculopapular rash. Symptom onset was 9-20 days after treatment initiation, coinciding with rituximab infusions. Both studies were amended to remove rituximab, but two of three additional patients had grade 3 rashes and one had grade 3 AST elevation. Both trials were permanently closed. The most common grade 3-4 adverse events were ALT elevation (two [67%] of three) and rash (two [67%] of three) for patients with mantle cell lymphoma and neutropenia (five [63%] of eight) and rash (four [50%] of eight) for patients with follicular lymphoma. The primary endpoint of safety and tolerability was not met. INTERPRETATION: The combination of idelalisib, lenalidomide, and rituximab in these trials is excessively toxic, and these trials serve as cautionary notes as new combinations are proposed. Off-target effects, drug-drug interactions, and emerging toxicities should be carefully assessed when investigating biological agents in combination and should never be done outside of a clinical trial setting. FUNDING: National Cancer Institute of the National Institutes of Health.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Smith SM, Pitcher BN, Jung SH, et al. Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials. Lancet Haematol. 2017. PMID: 28314699. doi:10.1016/S2352-3026(17)30028-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。